Sanofi Halts Multaq Trial Early Due To Cardiac Events
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi is facing another safety issue with its antiarrhythmic drug Multaq (dronedarone) with the termination of a Phase IIIb clinical trial in patients with permanent atrial fibrillation due to an increase in cardiovascular events.
You may also be interested in...
Multaq Panel Resolves Mortality Concerns, Looks At Restricted Claims
With two sets of conflicting data in front of them, the Cardiovascular and Renal Drugs Advisory Committee's first task for its review of Sanofi-Aventis' Multaq was to determine if the results were compatible. In the end, swayed by the positive findings in a narrower population, the committee supported a limited approval for dronedarone
ANDROMEDA Strain: Full Data Published From Multaq Trial
Details show death rates that led to Sanofi study's halt.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.